| pubmed-article:20693797 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0026724 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0007137 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0460004 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0040284 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0040688 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:20693797 | lifeskim:mentions | umls-concept:C1948023 | lld:lifeskim |
| pubmed-article:20693797 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20693797 | pubmed:dateCreated | 2010-8-31 | lld:pubmed |
| pubmed-article:20693797 | pubmed:abstractText | The monoclonal epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) was recently approved by the European Medicines Agency for the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) in combination with a platinum-based chemotherapy. Since the antibody has only a limited effect as a monotherapy, possible explanations for the synergistic effect with cisplatin are enhanced antibody-dependent cytoxicity and increased sensitivity to the drug. Most of our knowledge of EGFR biology in HNSCC is based on studies using EGFR inhibitors and/or antibodies. Our study was designed to evaluate the impact of EGFR stimulation on cisplatin-induced DNA damage. Therefore, tissue cultures were produced of tumor-free oropharyngeal mucosa biopsies of HNSCC patients and controls. In a previous study, overexpression of EGFR in tissue cultures from tumor patients compared to controls was confirmed by immunohistochemical staining. Twenty-four-hour stimulation of tissue cultures with transforming growth factor alpha (TGF-alpha), a specific EGFR ligand, resulted in a reduction of cisplatin-induced DNA damage by 35% in cases, whereas in controls TGF-alpha had no effect. This reflects a statistically significant increase in cellular chemoresistance to cisplatin following TGF-alpha stimulation and helps to further understand effects of EGFR antisense therapy in combination with chemotherapy. | lld:pubmed |
| pubmed-article:20693797 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20693797 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20693797 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20693797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20693797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20693797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20693797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20693797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20693797 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20693797 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20693797 | pubmed:issn | 1421-9794 | lld:pubmed |
| pubmed-article:20693797 | pubmed:author | pubmed-author:HarréusUlrich... | lld:pubmed |
| pubmed-article:20693797 | pubmed:author | pubmed-author:BaumeisterPhi... | lld:pubmed |
| pubmed-article:20693797 | pubmed:author | pubmed-author:ReiterMaximil... | lld:pubmed |
| pubmed-article:20693797 | pubmed:author | pubmed-author:Schwenk-Ziege... | lld:pubmed |
| pubmed-article:20693797 | pubmed:copyrightInfo | Copyright © 2010 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:20693797 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20693797 | pubmed:volume | 56 | lld:pubmed |
| pubmed-article:20693797 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20693797 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20693797 | pubmed:pagination | 268-74 | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:meshHeading | pubmed-meshheading:20693797... | lld:pubmed |
| pubmed-article:20693797 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20693797 | pubmed:articleTitle | Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin. | lld:pubmed |
| pubmed-article:20693797 | pubmed:affiliation | Department of Otolaryngology and Head and Neck Surgery, Ludwig Maximilian University, Munich, Germany. philipp.baumeister@med.uni-muenchen.de | lld:pubmed |
| pubmed-article:20693797 | pubmed:publicationType | Journal Article | lld:pubmed |
